---
title: "GTBP.US (GTBP.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GTBP.US/news.md"
symbol: "GTBP.US"
name: "GTBP.US"
parent: "https://longbridge.com/en/quote/GTBP.US.md"
datetime: "2026-05-20T22:08:04.799Z"
locales:
  - [en](https://longbridge.com/en/quote/GTBP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GTBP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GTBP.US/news.md)
---

# GTBP.US (GTBP.US) — Related News

### [B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic](https://longbridge.com/en/news/286806955.md)
*2026-05-18T18:22:00.000Z*
> GT Biopharma has initiated a Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a signifi

### [GT Biopharma reports Q1 results](https://longbridge.com/en/news/286567387.md)
*2026-05-15T12:42:20.000Z*
> GT Biopharma reports Q1 results

### [GTBP Q1'26 Earnings: EPS estimate is (0.08) USD](https://longbridge.com/en/news/286552803.md)
*2026-05-15T11:00:03.000Z*
> GTBP (GT Biopharma, Inc.) is set to announce its Q1'26 results on May 18, time not specified. The earnings are expected 

### [Hot pre-market trades in US stocks: GT Biopharma pre-market down 8.93%; Everspin Tech pre-market down 8.86%](https://longbridge.com/en/news/286537815.md)
*2026-05-15T09:17:48.000Z*
> GT Biopharma pre-market down 8.93%; Everspin Tech pre-market down 8.86%; HCW Biologics pre-market up 120.86%; Dreamland 

### [First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors](https://longbridge.com/en/news/286446313.md)
*2026-05-14T16:47:22.000Z*
> GT Biopharma, Inc. has dosed the first patient in a Phase 1 trial for GTB-5550, a B7-H3-targeted NK cell engager, markin

### [EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types](https://longbridge.com/en/news/286415809.md)
*2026-05-14T12:16:07.000Z*
> GT Biopharma has initiated a Phase 1 trial for its drug candidate GTB-5550, targeting B7-H3-positive solid tumors. The t

### [](https://longbridge.com/en/news/286424455.md)
*2026-05-14T13:11:18.000Z*
> GT Biopharma shares are trading higher after the company announced that the first patient was dosed in a Phase 1 dose es